QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vagin...( ANN ARBOR Mich. Sep...),Health

ANN ARBOR, Mich., Sept. 10 /PRNewswire/ -- QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA). This study, together with the recent completion of a long-term safety study for Ophena(TM), marks the end of the company's comprehensive Phase 3 efficacy and safety program for Ophena(TM) and positions QuatRx to file a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in early 2010.

This second phase 3 study of Ophena(TM) was a randomized, double-blind, placebo-controlled study with 919 women with vulvovaginal atrophy. The study was conducted at 116 sites in the United States. Among the cohort of 605 women in the study who identified dyspareunia as their most bothersome symptom, positive efficacy results were achieved in all four co-primary endpoints, including decrease in parabasal and superficial cells from vaginal smear, decrease in vaginal pH and improvement in the patient's most bothersome moderate to severe symptom of dyspareunia. The results showed highly statistically significant changes from baseline to week 12 compared to placebo in all four co-primary endpoints (p<0.0001). All women were supplied with a non-hormonal vaginal lubricant to be used as needed during the treatment period and the study results demonstrated efficacy above and beyond this lubricant usage, as also observed in the first Phase 3 study.

"These findings provide substantial additional evidence indicating the potential of Ophena(TM) to be a first-in-class non-estrogen drug for the treatment of vaginal atrophy," said Robert L. Zerbe, M.D., Chief Executive Offic
'/>"/>